Ipsen: acquisition of Albireo Pharma finalized
The acquisition complements Ipsen's portfolio with promising treatments for rare cholestatic liver diseases, innovative products with real potential in development, as well as scientific and commercial capabilities.
As part of the transaction, Ipsen is acquiring all the issued and outstanding shares of Albireo at a price of $42 per share in cash, plus a non-transferable guaranteed value certificate (GVC) of $10 per share.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction